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Abstract
Background: To determine the clinical presentation, current treatment and outcome of children with nonbacterial
inflammatory bone disease.
Methods: Retrospective multicenter study of patients entered into the Swiss Pediatric Rheumatology Working
Group registry with a diagnosis of chronic nonbacterial osteomyelitis (CNO) and synovitis acne pustulosis
hyperostosis osteitis (SAPHO) syndrome. The charts were reviewed for informations about disease presentation,
treatment, course and outcome.
Results: Forty-one children (31 girls and 10 boys) from 6 pediatric hospitals in Switzerland diagnosed between
1995 and 2010 were included in the study. The diagnosis was multifocal CNO (n = 33), unifocal CNO (n = 4) and
SAPHO syndrome (n = 4). Mean age at onset of CNO was 9.5 years (range 1.4–15.6) and mean follow-up time was
52 months (range 6–156 months). Most patients (n = 27) had a chronic persistent disease course (>6 months), 8
patients had a course with one or more relapses and 6 patients had only one episode of CNO. Forty nine percent
had received at least one course of antibiotics. In 57 % treatment with nonsteroidal anti-inflammatory drugs (NSAID)
was sufficient to control the disease. Twelve out of 16 children with NSAID failure subsequently received corticosteroids,
methotrexate, TNF α inhibitors, bisphosphonates or a combination of these drugs.
Conclusions: In a multicenter cohort of 41 children 22 % started with unifocal lesion with a significant diagnostic
delay. A higher proportion presented with chronic persistent disease than with a recurrent form. An osteomyelitis
in the pelvic region is significantly associated with other features of juvenile spondylarthritis.
Keywords: Nonbacterial osteitis, Chronic recurrent multifocal osteomyelitis, Sapho-Syndrome, Auto-inflammatory
disease, Spondylarthritis
Background
Chronic nonbacterial osteomyelitis (CNO) is a relatively
rare pediatric rheumatic disease first described by
Giedion et al. [1]. The 4 patients he reported suffered
from “symmetrical” bone pain. Pain remains the cardinal
feature of CNO. Symptoms of general disease as one would
expect in acute infectious osteomyelitis were absent.
After this first description the diagnosis CNO was
considered in children presenting with multifocal osteo-
myelitis [2, 3]. Observations of a greater diversity of the
clinical presentation of CNO followed [4, 5]. Nowadays
it is accepted that the presentation of aseptic osteomye-
litis can be either unifocal [6, 7] or multifocal, acute
(duration < 6 months) or chronic and the disease course
is not always recurrent. Consequently, new terms such as
nonbacterial osteitis (NBO) or chronic nonbacterial osteo-
myelitis (CNO) have been proposed [8, 9]. In some cases a
multifocal disease is only apparent on diagnostic imaging
as some bone lesions remain clinically asymptomatic.
This aseptic autoinflammatory condition of the muscu-
loskeletal system affects preferentially children, sometimes
adolescents. But osteitis is also part of the SAPHO syn-
drome which is more frequent in adults. 1987 Charmot et
al. coined the acronym synovitis, acne, pustulosis, hyper-
ostosis and osteitis (SAPHO) syndrome as a separate en-
tity [10]. This syndrome is mainly associated with
hyperostosis of the anterior chest wall and skin disorders
of the type of neutrophilic dermatoses. These dermatoses
are a group of inflammatory skin diseases of uncertain
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etiology [11] and include palmoplantar pustulosis (PPP),
psoriasis, acne fulminans, neutrophilic eccrine hidradeni-
tis, Sweet syndrome and pyoderma gangrenosum. In fact,
CNO can be accompanied with neutrophilic dermatoses
as aforementioned as well. This association, first described
by Probst 1976 [12] can be seen in a sizeable proportion
of cases and seems to be more common with increasing
age of the patient [13, 14]. Therefore, it has been hypothe-
sized that CNO may be the pediatric form of SAPHO
syndrome [15]. Other authors have postulated that osteitis
is the common component of a disease spectrum with
different clinical presentations but the same etiology and
pathophysiology [16].
Also an evolution of CNO towards spondylarthritis
has been described in children and adults [17]. Spondy-
larthritis (SpA) in children is often undifferentiated at
onset. The signs and symptoms at disease onset differ
from those seen in adults, with inflammatory back pain
being less common, reflecting the rare involvement of
the sacroiliac and vertebral joints in juvenile disease. By
contrast, hip and peripheral arthritis together with
enthesitis are common presenting features in juvenile
onset spondylarthritis [18]. In our study we compared a
group of patients qualifying for juvenile spondylarthritis
with the total cohort in order to evaluate whether these
two groups can be distinguished early on. The next aim
was to determine the features of nonbacterial osteitis in
pediatric patients, the management, the course of the
disease and the outcome.
Patients and Methods
The Swiss Pediatric Rheumatology Working Group regis-
try included all patients seen in the 6 pediatric rheumatol-
ogy centers throughout Switzerland. The registry was
searched for the diagnoses SAPHO syndrome and CRMO/
CNO. In addition, other specialties such as pediatric infec-
tious diseases, orthopedics or pediatric surgery at the same
6 centers were asked to contribute patients treated by
them, if available. All medical records were reviewed, and
data about history and clinical presentation, markers of
inflammation and bone metabolism, HLA-B27, histo-
logical and radiological findings at presentation and
during follow-up, medication used and outcome were
collected using a standardized form and entered into an
Excel spread sheet.
Based on the course of their disease patients were
assigned to 3 different groups: 1. Patients with an acute
form (single course less than 6 months duration); 2. Pa-
tients with a relapsing form (at least 2 flares with a
symptom-free period in between without treatment); 3.
Patients with a persistent form with complaints with or
without treatment more than 6 months. Table 1
In addition, we divided the patients in one group with
osteomyelitis +/− peripheral arthritis and another group
with additional features of juvenile onset spondylarthritis
such as axial arthritis, enthesitis, psoriasis and PPP, acute
iridocyclitis, inflammatory bowel disease, HLA-B27 posi-
tivity or a family history of HLA-B27 associated disease
(Table 2). Patients had to present at least one clinical fea-
ture (axial arthritis, enthesitis, psoriasis, PPP, acute uveitis
or IBD) to be included into this group.
Mean, standard deviation and statistical significance
(T-Test) was performed using Excel 2007 from Microsoft
Corporation (Redmond, WA 98052 USA). The study
was approved by the institutional ethics review boards of
all participating centers.
Results
Patients’ characteristics and clinical presentation
We found 41 patients diagnosed between 1995 and 2010
with CNO (37 cases) or SAPHO syndrome (4 cases). Pa-
tients’ characteristics are shown in Table 2. Median age
at onset was 9.5 ± 3.1 years (range 1.4–15 years) with a
female predominance of 3:1. As shown in Fig. 1 most pa-
tients present between 7 and 12 years of age. The mean
diagnostic delay was 8 months (range 1–64 months).
Diagnostic delay in the group with unifocal disease was
longer with 12.1 months versus 7 months in multifocal
onset (p = 0.03). Patients were followed up for a median
period of 52 months (range 0.5–14 years).
Diagnosis
For all but 3 patients conventional X-rays were available
for diagnosis. The most common additional diagnostic
imaging method used was MRI (36 patients) for local
lesions. Only in 5 / 41 patients a bone scintigraphy or
CT was made instead of MRI. Four of the 41 patients
initially had a normal radiograph of the symptomatic
region. In these 4 patients the MRI showed typical
findings of marrow edema with hypointense lesions on
T1-weighted or hyperintense lesions on T2- weighted
images and/or abnormal enhancement after intravenous
administration of gadolinium-based contrast medium. In
these 4 cases characteristic conventional radiographic
signs such as osteolytic and/or sclerotic changes or peri-
ostal reactions were absent.
Bone biopsies were available for 29 out of 41 patients
(71 %). Histological investigations showed nonspecific,
inflammatory changes with granulocytic infiltration and
fibrotic and/or hyperostotic regeneration.
At diagnosis, ESR was elevated (>15 mm/h) in 82 %
(median 34 mm/h, range 5–83). Pathological laboratory
test results such as ESR, CRP and thrombocytosis did
not correlate with clinical signs of inflammation such as
swelling, redness, local warmth or fever. HLA-B27 was
positive in 5 / 24 patients tested (21 %). Two of these 5
patients had associated arthritis, psoriasis or palmoplan-
tar pustulosis and had a diagnosis of SAPHO syndrome,
Kaiser et al. Pediatric Rheumatology  (2015) 13:25 Page 2 of 7
Table 1 Clinical and laboratory features of patients CNO
Patient Sex (mm/ h) Age ESR Course Immun-suppressives TNF Bisphosphonates Follow up
1 M 4.7y 32 Relapsing No No No 5.8y
2 F 9.6y 12 Persistent No No No 0.7y
3 M 1.4y 83 Persistent MTX No Neridronat 8.7y
4 F 11.4y 16 Relapsing No No No 3.8y
5 M 10.1y 38 Persistent MTX No Neridronat 0.8y
6 F 8.3y 8 Persistent MTX No No 2.5y
7 F 7.5y 46 Acute No No No
8 F 1.9y 30 Acute No No No 15y
9 F 13.8y 25 Persistent - - - 1.9y
10 M 9.5y 49 Relapsing Steroids No No 7y
11 F 10.5y 54 Relapsing Steroids No PAM 2.6y
12 F 4.1y 61 Relapsing No No No 7.1y
13 F 8.8y 35 Relapsing Steroids Yes PAM 10y
14 F 12.5y 7 Relapsing No Yes No 4.8y
15 F 12.0y 60 Persistent No Yes No 10.3y
16 F 12.5y 57 Acute No No No 0.9y
17 F 9.0y - Persistent Steroids yes PAM/Alendronat 5y
18 M 11.7y 56 Persistent No No No 2y
19 M 15.8y 18 Acute No No No 6.3y
20 F 11.4 y 5 Persistent Steroids/MTX No No 1.5y
21 F 11.5y 19 Persistent Yes No No 1.7y
22 F 9.9y 17 Persistent No No No 7.5y
23 F 6.0y 6 Persistent No No No 13y
24 F 10.5y 34 Persistent Steroids/MTX No No 8y
25 F 9.9y 40 Acute No No No 0.8y
26 F 11.5y 35 Persistent No Yes No 2.4y
27 M 15.3y 8 Persistent No No No 1.6y
28 F 10.5y 20 Persistent No No No 4.2y
29 M 8.5y 55 Persistent No No No 0.5y
30 F 9.2y 42 Persistent No No No 3y
31 F 14.7y 18 Persistent No No No 2.8y
32 F 8.9y 36 Persistent No No No 4.8y
33 F 9.3y 52 Persistent No No No 1.2y
34 F 7.5y 33 Acute No No No 6.3y
35 F 8.9y 43 Persistent MTX Yes No 5.5y
36 F 1.8y - Persistent MTX No No 1.y
37 M 8.7y 31 Persistent No No No 0.8y
38 F 6.1y 21 Persistent Steroids/MTX Yes No 7.5y
39 F 9.5y 6 Persistent No No No 1.3y
40 M 5.8y 53 Relapsing Steroids/MTX Yes No 2.1y
41 F 10.3y 62 Persistent Steroids/MTX No No 1.9y
In italics: Patients diagnosed with SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome
Acute form: single course of <6 months duration. Relapsing form: at least 2 flares with remission in between. Persistent form with complaints with or without
treatment for ≥6 months. NSAID sufficient to control pain
PAM pamidronat,n.d. not done, PPP palmoplantar Pustulosis
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both had sacroiliitis. Two other girls of these HLA-B27
positive patients had a vertebral osteitis.
Nine of the 41 patients had symptoms related to spon-
dylarthropathy as sacroiliitis, costo-vertebral arthritis or
psoriasis. There were no differences between this sub-
group and the non-spondylarthropathy patients in regards
to sex, age, ESR at onset, disease course and remission
rate. The only significant difference was the occurrence of
osteomyelitis in the pelvic region, which was present in all
9 patients of the spondylarthropathy subgroup but only in
1/32 patients of the other patients. This female patient
with lesions at the acetabulum (Fig. 2) didn’t present a
sacroiliitis or psoriatic skin lesion, but HLA-B27 was
tested positive. Of the spondylarthritis group 6/9 patients
had a radiological confirmed sacroiliitis, 5/9 had a psori-
atic skin lesion. Overall 13 of 41 patients showed a spinal
osteomyelitic lesion, thereof 5 at thoracic spine, 1 lumbar
spine und 7 at the sacrum. Of these 13 patients with axial
osteomyelitis only 6 patients had additional symptoms re-
lated to spondylarthropathy.
Associated diseases
Skin lesions were present in 6 out of 41 children (17 %).
Three patients presented with typical palmoplantar pus-
tulosis. Psoriasis or acne was described in one patient
each, 1 patient had both psoriasis and acne.
An associated autoimmune disease was seen in 2 out
of 41 patients: 1 patient had a diagnosis of unclassified
panniculitis and a girl had an additional diagnosis of
ANA-positive juvenile idiopathic oligoarthritis with uve-
itis. No patient had inflammatory bowel disease.
Treatment
Nineteen patients (46 %) initially received antibiotic
treatment, 4 out of 9 patients with unifocal and 14 out
of 32 with multifocal presentation. We found a statisti-
cally significant difference in the use of antibiotics across
the centers (p = 0.02), but not according to disease char-
acteristics such as unifocal presentation. Six patients also
underwent surgery (2 bone resections, 4 bone curet-
tages). Thirty-seven (90 %) received NSAIDs as anti-
Table 2 Characteristics of patients with features of juvenile spondylarthritis
Patient Gender Age HLA-B27 ANA Derma FH Axial arthritis Peripheral arthritis
8 F 1.9y pos pos PPP neg No Yes
9 F 13.5y neg n.d. No neg Sacroileitis No
14 F 12.5y neg neg No neg Sacroileitis Yes
15 F 12.0y neg n.d. No - Sacroileitis Yes
19 M 15.7y n.d. n.d. No - Sacroileitis No
24 F 10.1y neg neg Psoriasis - Costo-vertebral No
35 F 8.9y pos neg Psoriasis - Sacroileitis Yes
36 F 10.8y pos neg PPP pos Yes Yes
40 M 5.8y n.d. neg PPP No No No
FH Family History, PPP Palmoplantar Pustulosis
Fig. 1 Distribution of patients by age at disease onset
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inflammatory drug. In 21/37 (57 %) this treatment was
sufficient to control pain. Since radiologic follow up was
not part of our study, the radiologic evolution of the bone
lesions in these patients are not known. After failure of
NSAIDs 12 children were treated either with systemic ste-
roids (7 patients), methotrexate (7), TNF-blockers (7),
anakinra (1) or bisphosphonates (5). Eleven out of these
12 patients (96 %) were treated with different drugs se-
quentially. Of the 7 patients treated with methotrexate, 6
received the drug for a period of 3–24 months without
obvious improvement. Only 1 patient with SAPHO syn-
drome received methotrexate for 3.8 years, but the indica-
tion for MTX use in this case was peripheral arthritis. In
our series no patient was treated with sulfasalazine.
Bisphosphonate was used in 5 patients with improve-
ment in 2. One girl received a single cycle (3 infusions)
of pamidronate and thereafter was in continuous remis-
sion until the last follow-up 20 months later. The other
patient experienced relief of his bone pains with neridro-
nate infusions 9 years after disease onset, but was not
able to stop NSAID treatment. Only in 1 patient a com-
bination of bisphosphonates with TNF-blocker was used.
This girl was successfully treated during her fifth disease
relapse with adalimumab and pamidronate.
Of the 8 patients treated with biologics only 2 were
treated successfully for osteomyelitis with etanercept
over a period of 12 and 28 months respectively. One pa-
tient had adalimumab for arthritis but had persistent
osteomyelitis despite improvement of arthritis. In 2 cases
treatment with TNF-blockers was stopped after a short
time because of side effects (skin infection, allergic reac-
tion) and in further 2 cases treatment was unsuccessful.
One patient had anakinra without improvement.
In the 13 patients (32 %) with vertebral lesions the
therapeutic approach and response to treatment was not
different from the group without vertebral lesions.
Disease course
At the onset of symptoms 9 patients (22 %) had a unifo-
cal osteitis. Five of these 9 patients developed multifocal
disease later on. The mean observation time in the uni-
focal course was 24 months in contrast to 72 months in
the multifocal course of disease. Also, the only patient in
our cohort with mandibular osteitis had only one disease
focus. Six patients had an acute form and were symptom-
free after 6 months during follow up. A non-recurrent,
persistent form of illness was noted in 66 % (27 patients)
whereas 8 patients (19 %) had a relapsing course. The pa-
tients with the recurrent course experienced between 1
and 5 relapses. The median time between the relapses was
24.5 months (range 7 to 90 months). Observation time in
the group of the persistent form was 43.8 months; in the
relapsing form 64.4 months. Nine children with chronic
disease needed treatment for more than 5 years, some
with NSAIDs alone, some with different drugs. The lon-
gest course of active illness was 13 years.
Complications included fractures at the site of inflam-
mation in 2 patients. Both had a pathological fracture of
a vertebral body at diagnosis. Another patient suffered
from scoliosis due to wedging of a vertebral body, fur-
thermore 1 patient had severe hyperostotic bone lesions
and yet another one had bone length difference follow-
ing surgical intervention.
Discussion
In this retrospective study we report the disease charac-
teristics of a group of 41 patients with chronic non-
bacterial osteomyelitis collected from 6 Swiss pediatric
centers. We were able to show the huge diversity of
presentation, disease course and response to therapy.
Diagnosis
Similar to other pediatric series, mean age at onset of
nonbacterial osteomyelitis was 9.5 years with a predom-
inance of females of 3:1 [19, 20]. CNO still remains a
difficult diagnosis, so mean diagnostic delay in our co-
hort was 8 months. Possible reasons include the fact that
plain radiographs are not sensitive enough to detect
osteomyelitis or unifocal lesions were misdiagnosed as
acute infectious osteomyelitis. This may also explain
why the diagnostic delay in patients with a unifocal pres-
entation was significant longer than in multifocal onset.
Obviously histological examination is non-specific, but
biopsy was helpful to exclude diseases like Langerhans
cell Histiocytosis X, benign or malignant bone tumors
especially in unifocal lesions [21].
Although today we assume that CNO belong to
the family of autoinflammatory diseases with osseous
manifestation, many patients with CNO and SAPHO-
Syndrome have beside the osteitis, symptoms from the
spectrum of the spondylarthritis as an axial involvement,
Fig. 2 Case 1: Imaging data of CNO involving pelvis in a 12-year-old
girl. Coronal STIR MRI reveal increased signal in the right and
left acetabulum
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the occurrence of IBD and an increased prevalence of
the HLA-B27 phenotype [15]. This raises the question,
whether CNO is a disease with different subgroups.
Based on accompanying features we divided our patients
into 2 subgroups, with and without features of juvenile
spondylarthritis. In our cohort only 6 patients had arth-
ritis, of which 5 had also sacroiliitis. Arthritis in CNO
has been reported in up to 80 % in one serie [9], but
most series report about 30 % (17, 23). Comparing the
two subgroups we found no significant difference re-
garding disease presentation and course. But interest-
ingly pelvic osteomyelitis was significantly associated
with features of spondylarthritis, as all patients from the
spondylarthritis group had an osteomyelitis in this
localization but only one of the other 32 patients had.
The pelvis is a typical site of CNO with 11–34 % of
patients affected [8, 22–24], which is consistent with our
findings (25 %). This is a fact which may be helpful in
the future to distinguish subgroups of patients with
CNO. On the other hand we couldn’t find a difference
in spinal involvement comparing the two groups. Hence
in our study-population an axial lesion is not a criteria
for the evolution of spondylarthritis, as it can be seen in
CNO. The frequency of HLA-B27 is low in CNO com-
pared to patients with ERA, 21 % in our population.
Treatment
Pathogens such as proprionebacterium acnes are no lon-
ger considered relevant in the pathogenesis of CNO, as
today CNO is placed in the category of autoinflamma-
tory diseases. Nevertheless, half of our patients were
treated with antibiotics first, but with a significant differ-
ence across the centers. There was no difference be-
tween the use of antibiotics for unifocal or multifocal
presentation.
Fifty-seven percent of our patients responded well to
the treatment with nonsteroidal anti-inflammatory drugs
(NSAID), which is in keeping with data published in
other reports [25, 26]. NSAID can control pain, which
doesn’t mean there is remission radiologically [26]. In
case pain does not respond to NSAIDs, a short course of
corticosteroids may be an alternative. Methotrexat (MTX)
is an approved drug in children with rheumatologic disor-
ders, also several cases of SAPHO-syndrome responsive to
methotrexat therapy have been reported [15]. Neverthe-
less, MTX therapy was ceased in all but one of our pa-
tients because of lack of improvement. In a cohort of 70
children with CNO reported by Borzutzky et al. [24] 20 %
had clinical remission treated with methotrexate. They ob-
served the highest rate of clinical remission with TNF-α
inhibitors (46 %). Several other case reports describe the
efficacy of anti-TNFα therapy [27, 28]. In our population
we found mixed success with TNFα-agonists as well as
with bisphosphonate therapy.
The good effect of bisphosphonate therapy has been
documented in several reports [29–31]. Rodrick et al.
found a good or moderately good response in 8 out of
11 patients (73 %) to pamidronate therapy, bone lesions
resolved or showed significant improvement in the second
WB-MRI. The improvement of bone inflammation after
pamidronate therapy was also reported by Hofmann et al.
[32]. Although no complete radiological remission could
be achieved, bisphosphonates are an optional treatment
for patients with vertebral lesion to prevent fractures and
orthopedic complications as shown by Hospach et al. [33],
while fractures occurred often (up to 40 %) in vertebral in-
volvement [34]. However in the face of the long half-life
time of bisphosphonates and the side effects, the indica-
tion for bisphosphonate therapy has to be made carefully.
The inclusion of patients with this rare disease in a
large registry (for example www.printo.it/eurofever) as
initiated by the Paediatric Rheumatology International
Trials Organisation PRINTO will be helpful to deter-
mine an effective treatment.
Disease course
In contrast to the previous assumption that nonbacterial
osteomyelitis is a recurrent disease, the majority of our
patients (67.5 %) suffered from a chronic persistent ill-
ness. This is a higher proportion than described in other
cohorts. Gikas at al found 49 % with a non-recurrent
disease pattern [22].
We saw that disease activity may persist for years or
even decades. In our cohort 9 children (22 %) with
chronic disease needed treatment for more than 5 years.
The longest course of active illness was 13 years. Only
30 % came into remission, which is similar to the find-
ings of Catalano-Pons et al. [19] in an equally large co-
hort. In their study 58.6 % of patients had active disease
at follow up (0.5–15 years after diagnosis). More than
25 % of the cohort examined by Huber et al. [23] had
persistent CNO activity at the time of evaluation a me-
dian of 12 years later and after a median overall duration
of active disease of 5.7 years. In the follow-up study of
Duffy et al. [35] the duration of symptoms ranged from
2.5 to 20 years. Huber et al. [30] conclude that CRMO
usually has a favorable evolution with no major sequelae.
This is in keeping with our findings, where also only 4 pa-
tients had orthopedic complications during the observa-
tion period of 52 months (range 6 months to 14 years).
Vittecoq et al. concluded [17] that CRMO usually
evolved to spondylarthropathy. Despite special consider-
ations of these features we can’t agree with this evolu-
tion in our cohort, because 32 of our 41 patients still
had osteomyelitis at the end of the observation period.
As described by Zibroswska-Bech et al. [36] we found
the extra-osseous manifestation typically present at the
time of diagnosis.
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Our study is limited by the retrospective multicenter
and multidisciplinary design, which does not allow for
analyses regarding disease details and treatment. However,
despite these shortcomings we think our findings may still
be helpful to improve knowledge and enhance awareness
about this unique disease across the involved disciplines.
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